# A Pilot Trial of Oral Topotecan for the Treatment of Refractory Advanced Solid Neoplasms Expressing HIF-1a

> **NCT00117013** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 16 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** Fluorine-19-Fluoroded Xyglucose
- **DRUG:** Topotecan

## Key facts

- **NCT ID:** NCT00117013
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06-28
- **Primary completion:** 2010-10-25
- **Final completion:** 2010-10-25
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2017-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00117013

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00117013, "A Pilot Trial of Oral Topotecan for the Treatment of Refractory Advanced Solid Neoplasms Expressing HIF-1a". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00117013. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*